Management of Warfarin for Colonoscopy in Patients with History of DVT
For patients with a history of DVT undergoing colonoscopy, the management depends on whether polypectomy is anticipated: continue warfarin for diagnostic colonoscopy only, but stop warfarin 5 days before the procedure if polypectomy is planned—and critically, do NOT use heparin bridging in either scenario. 1, 2
Risk Stratification: Procedure and Thrombotic Risk
Colonoscopy Risk Classification
- Diagnostic colonoscopy with biopsy only = Low-risk procedure 1
- Colonoscopy with polypectomy = High-risk procedure 1
Thrombotic Risk Assessment for DVT History
- Low thrombotic risk: Single DVT episode >12 months ago, provoked by transient risk factor, no recurrence 1, 2
- High thrombotic risk: Unprovoked DVT, recurrent VTE, DVT within past 3 months, active cancer, or multiple risk factors 1, 2
Most patients with remote DVT history are considered low thrombotic risk at the time of elective colonoscopy 2, 3
Management Algorithm
For Diagnostic Colonoscopy (No Polypectomy Expected)
Continue warfarin without interruption 1
- Check INR during the week before colonoscopy 1
- Ensure INR is within therapeutic range (2.0-3.0) and does not exceed it 1, 4
- If INR is within therapeutic range, continue usual daily warfarin dose 1
- If INR is above therapeutic range but <5, reduce warfarin dose until INR returns to therapeutic range 1
- If INR >5, defer the procedure and contact anticoagulation clinic for management 1
For Colonoscopy with Anticipated Polypectomy
Low Thrombotic Risk Patients (Most DVT Patients)
Stop warfarin 5 days before the procedure WITHOUT heparin bridging 1, 2
- Discontinue warfarin 5 days pre-procedure 1
- Check INR immediately before colonoscopy to ensure <1.5 1
- Resume warfarin the evening of the procedure at usual dose 1
- Check INR 1 week later to confirm adequate anticoagulation 1
- Do NOT use bridging anticoagulation 2
High Thrombotic Risk Patients (Rare in Elective Setting)
Stop warfarin 5 days before with LMWH bridging 1
- Stop warfarin 5 days pre-procedure 1
- Start therapeutic-dose LMWH 2 days after stopping warfarin 1
- Give last LMWH dose at least 24 hours before the procedure 1
- Check INR pre-procedure to ensure <1.5 1
- Resume warfarin evening of procedure at usual dose 1
- Restart therapeutic-dose LMWH the day after procedure 1
- Continue LMWH until therapeutic INR achieved 1
Critical Evidence on Bridging
The evidence strongly argues against heparin bridging for most patients:
- The American College of Chest Physicians guidelines specifically recommend against heparin bridging for colonoscopy with polypectomy in patients on warfarin 2
- A randomized trial showed 12.0% major bleeding with warfarin interruption plus heparin bridging versus 4.7% with warfarin continuation (though not statistically significant due to small sample size) 2
- A large retrospective cohort study found bridging therapy increased bleeding risk 17-fold (HR 17.2,95% CI 3.9-75.1) with no reduction in VTE recurrence 3
- Recent Japanese data showed significantly lower bleeding rates with continued warfarin (1.3%) versus heparin replacement (10.1%) for colorectal endoscopic resection 5
Common Pitfalls to Avoid
- Do not routinely bridge patients with remote DVT history—79% of patients requiring warfarin interruption for procedures are at low thrombotic risk and bridging dramatically increases bleeding without preventing thrombosis 2, 3
- Do not perform polypectomy if INR remains elevated—ensure INR <1.5 before high-risk interventions 1
- Do not forget to restart warfarin promptly—resume the evening of the procedure to minimize time off anticoagulation 1
- Do not assume all DVT patients need bridging—only those with very recent VTE (<3 months), recurrent unprovoked VTE, or active cancer typically qualify as high thrombotic risk 1, 2
Target INR for DVT Patients
For patients with DVT history, the target INR is 2.5 (range 2.0-3.0) for all treatment durations 4